Table 2.
Actionable targeted mutations in this cohort.
| Actionable targeted mutations | Case number | Mutational frequency of actionable mutated genes (n/122) | Targeted drug |
|---|---|---|---|
| CDKN2A | 42 | 34.4% | Abemaciclib, Palbociclib, Ribociclib |
| PTEN | 23 | 18.9% | GSK2636771, AZD8186 |
| NF1 | 17 | 13.9% | Trametinib, Cobimetinib |
| FGFR1 | 14 | 11.4% | AZD4547, Debio1347, Infigratinib, Erdafitinib |
| KRAS | 11 | 9.0% | Binimetinib, Trametinib, Cobimetinib |
| NTRK3 | 9 | 7.4% | Entrectinib |
| ARID1A | 5 | 4.1% | PLX2853 |
| BRAF | 5 | 4.1% | PLX8394 |
| FGFR2 | 4 | 3.3% | Infigratinib, AZD4547, Debio1347, Erdafitinib |
| FGFR3 | 4 | 3.3% | Erdafitinib, Infigratinib, Debio1347, AZD4547 |
| MET | 4 | 3.3% | Crizotinib |
| MTOR | 2 | 1.6% | Temsirolimus, Everolimus |
| NTRK1 | 2 | 1.6% | Entrectinib |
| NTRK2 | 2 | 1.6% | Entrectinib |
| CDK12 | 1 | 0.8% | Pembrolizumab, Cemiplimab, Nivolumab |
| Total | 145 |